Fiala

Peptide library › Metabolic & weight

Efpeglenatide

In clinical trialsMetabolic & weight

Long-acting experimental GLP-1 medicine that cut heart and kidney events in people with type 2 diabetes in a large trial.

What people use it for

What Efpeglenatide does in the body

An exendin-4-like GLP-1 receptor agonist attached to a carrier protein so it lasts much longer. It raises insulin when blood sugar is high, lowers glucagon, slows stomach emptying and reduces appetite.

Strength of evidence

Strong for its stage: the AMPLITUDE-O trial in about 4,000 people with type 2 diabetes found fewer major heart events and kidney problems than placebo.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

Investigational. Not approved by the FDA or EMA.

How it's taken

Route: Injection under the skin, once weekly (in trials)

How long it lasts (half-life): Long-acting; designed for weekly or less frequent dosing

Keep track of Efpeglenatide privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Efpeglenatide in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Metabolic & weight